|Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations|
KA Phillips, IM Collins, RL Milne, SA McLachlan, M Friedlander, M Hickey, ...
Human Reproduction 31 (5), 1126-1132, 2016
|Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers|
IM Collins, RL Milne, PC Weideman, SA McLachlan, ML Friedlander, ...
Med J Aust 199 (10), 680-3, 2013
|Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into …|
IM Collins, RL Milne, SA McLachlan, M Friedlander, M Hickey, ...
J Clin Oncol 31 (31), 3920-5, 2013
|The tubal hypothesis of ovarian cancer: caution needed|
IM Collins, SM Domchek, DG Huntsman, G Mitchell
The lancet oncology 12 (12), 1089-1091, 2011
|Assessing and managing breast cancer risk: Clinicians' current practice and future needs|
IM Collins, E Steel, GB Mann, JD Emery, A Bickerstaffe, A Trainer, ...
The Breast 23 (5), 644-650, 2014
|Women’s preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique|
AF Ralph, B Ager, ML Bell, IM Collins, L Andrews, K Tucker, N O’Reilly, ...
SpringerPlus 3 (1), 264, 2014
|iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management|
IM Collins, A Bickerstaffe, T Ranaweera, S Maddumarachchi, L Keogh, ...
Breast cancer research and treatment 156 (1), 171-182, 2016
|Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory|
AF Ralph, B Ager, ML Bell, IM Collins, L Andrews, K Tucker, KA Phillips, ...
Patient education and counseling 96 (1), 106-112, 2014
|Strategies for fertility preservation after chemotherapy awareness among Irish Cancer specialists|
IM Collins, MJ Kennedy
Irish Medical Journal, 2011
|Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?|
KA Phillips, EJ Steel, I Collins, J Emery, M Pirotta, GB Mann, P Butow, ...
Australian journal of primary health 22 (3), 255-261, 2016
|Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls|
IM Collins, R Roberts-Thomson, D Faulkner, D Rischin, M Friedlander, ...
International Journal of Gynecological Cancer 21 (7), 1213, 2011
|Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor|
IM Collins, P Beddy, KJ O'BYRNE
Acta oncologica 49 (6), 872-874, 2010
|A Role for IGF-1R–Targeted Therapies in Small-Cell Lung Cancer?|
K Gately, I Collins, L Forde, B Al-Alao, V Young, M Gerg, F Feuerhake, ...
Clinical Lung Cancer 12 (1), 38-42, 2011
|Electronic clinical decision support systems attitudes and barriers to use in the oncology setting.|
IM Collins, O Breathnach, P Felle
Irish Journal of Medical Science, 2012
|Terminology and Details of the Diagnostic Process for Testis Cancer|
SS Connolly, PJA Daly, MSJ Floyd Jr, IM Collins, R Grainger, JA Thornhill
The Journal of urology 185 (3), 876-880, 2011
|Clinical Decision Aids in Colon Cancer; A Comparison of Two Predictive Nomograms|
IM Collins, F Kelleher, C Stuart, M Collins, J Kennedy
Clinical Colorectal Cancer, 2011
|Novel Approaches to Treatment of Leiomyosarcomas|
IM Collins, DM Thomas
Current oncology reports, 1-7, 2011
|Adjuvant trastuzumab in HER2-positive breast cancer.|
IM Collins, P Francis, L Mileshkin
The New England journal of medicine 366 (7), 664; author reply 664, 2012
|Bisphosphonate induced osteonecrosis of the jaws: Unravelling uncertainty in disease causality|
FC Kelleher, M McKenna, C Collins, G Brady, I Collins, J Crown
Acta oncologica 46 (5), 702-704, 2007
|Rechallenge with imatinib in GIST: is more always RIGHT?|
D Urban, J Lewin, IM Collins, J Mooi, M Jefford
The Lancet Oncology 15 (1), e2-e3, 2014